
VistaGen Therapeutics (VTGN) P/E Ratio
P/E Ratio as of Jul 2, 2025: -1.29
Average-1.39
Median-1.42
Minimum-1.53
Maximum-1.24
-1.29
Past Month+0.34 (20.86%)
The P/E ratio for VistaGen Therapeutics (VTGN) is -1.29 as of Jul 2, 2025. This represents a decrease of -30.65% compared to its 12-month average P/E ratio of -1.86. A higher P/E ratio suggests that investors expect strong future earnings growth, while a lower P/E ratio may indicate a potentially undervalued stock or slowing growth.
VistaGen Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
VistaGen Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing VistaGen Therapeutics to industry peers.
VistaGen Therapeutics P/E Ratio Formula = Stock Price ÷ Earnings Per Share (EPS)
VistaGen Therapeutics’s P/E ratio represents the valuation of the company based on its earnings. It’s calculated by dividing the company’s latest stock price by its diluted earnings per share (EPS) over the past 12 months. The P/E ratio helps investors assess how much they are paying for each dollar of earnings, offering valuable insights when comparing VistaGen Therapeutics to industry peers.
VistaGen Therapeutics (VTGN) P/E Ratio Insights
See VistaGen Therapeutics’s latest P/E ratio, historical trends, and valuation insights with AI-powered fundamental data and custom analysis.
Start investing in VistaGen Therapeutics (VTGN)
Order type
Buy in
Order amount
Est. shares
0 shares
VistaGen Therapeutics (VTGN) P/E Ratio Historic Data
Date | Stock price | P/E ratio |
---|---|---|
Jul 1, 2025 | $2.01 | -1.27 |
Jun 2, 2025 | $2.425 | -1.53 |
May 1, 2025 | $2.36 | -1.49 |
Apr 1, 2025 | $2.34 | -1.48 |
Mar 3, 2025 | $2.49 | -1.57 |
Feb 3, 2025 | $2.91 | -2.17 |
Jan 2, 2025 | $3.315 | -2.47 |
VistaGen Therapeutics (VTGN) End of Year P/E Ratio
Date | P/E ratio | Change |
---|---|---|
2025 | -1.29 | -41.36% |
2024 | -2.20 | +101.83% |
2023 | -1.09 | +230.30% |
2022 | -0.33 | -93.80% |
2021 | -5.32 | -26.52% |
2020 | -7.24 | — |
FAQs About VistaGen Therapeutics (VTGN) P/E ratio
The latest P/E ratio of VistaGen Therapeutics (VTGN) is -1.29, as of Jul 2, 2025. This is calculated based on its current stock price and earnings per share (EPS).
VistaGen Therapeutics’s last 12-month average P/E ratio is -1.86, compared to its current P/E ratio of -1.29. This reflects a decrease of -30.65%.
VistaGen Therapeutics’s current P/E ratio of -1.29 is lower than its last 12-month average P/E of -1.86. A higher P/E can indicate strong future growth expectations, while a lower P/E might suggest undervaluation.
VistaGen Therapeutics’s average P/E ratio over the last 3 years is -1.24. Comparing this to the current P/E helps assess recent valuation trends and whether the stock is trading above or below its mid-term historical range.
VistaGen Therapeutics’s average P/E ratio over the last 5 years is -2.89. A deviation from this historical average may indicate shifts in growth expectations, profitability, or broader market conditions affecting valuation.